Genetic or pharmacological ablation of AMPKα in several syngeneic mouse models of different cancer types inhibited the immunosuppressive potential of MDSCs, induced CD8+ T cell infiltration into tumor sites, and improved efficacy of immunotherapy (Trillo-Tinoco et al., 2019). The gene discussed is CD8A; the disease is cancer.